| Pharmaceutical Information |
| Drug Name |
Pazopanib |
| Drug ID |
BADD_D01687 |
| Description |
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. |
| Indications and Usage |
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
| Marketing Status |
approved |
| ATC Code |
L01EX03 |
| DrugBank ID |
DB06589
|
| KEGG ID |
D05380
|
| MeSH ID |
C516667
|
| PubChem ID |
10113978
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
7RN5DR86CK
|
| Synonyms |
pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient |
|
| Chemical Information |
| Molecular Formula |
C21H23N7O2S |
| CAS Registry Number |
444731-52-6 |
| SMILES |
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
